KR102468874B1 - 통증에 대하여 다중모드 활성을 갖는 １-옥사-４,９-디아자스피로 운데칸 화합물의 알킬 유도체 - Google Patents

통증에 대하여 다중모드 활성을 갖는 １-옥사-４,９-디아자스피로 운데칸 화합물의 알킬 유도체 Download PDF

Info

Publication number
KR102468874B1
KR102468874B1 KR1020167036612A KR20167036612A KR102468874B1 KR 102468874 B1 KR102468874 B1 KR 102468874B1 KR 1020167036612 A KR1020167036612 A KR 1020167036612A KR 20167036612 A KR20167036612 A KR 20167036612A KR 102468874 B1 KR102468874 B1 KR 102468874B1
Authority
KR
South Korea
Prior art keywords
unsubstituted
oxa
ethyl
substituted
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167036612A
Other languages
English (en)
Korean (ko)
Other versions
KR20170012444A (ko
Inventor
마리나 비르길리-베르나도
모니카 알론소-살마
카를로스 알레그레트-모리나
카르멘 알만사-로살레스
모니카 가르시아 로페즈
Original Assignee
에스테베 파마슈티칼스 에스에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에스테베 파마슈티칼스 에스에이 filed Critical 에스테베 파마슈티칼스 에스에이
Publication of KR20170012444A publication Critical patent/KR20170012444A/ko
Application granted granted Critical
Publication of KR102468874B1 publication Critical patent/KR102468874B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020167036612A 2014-06-02 2015-06-02 통증에 대하여 다중모드 활성을 갖는 １-옥사-４,９-디아자스피로 운데칸 화합물의 알킬 유도체 Active KR102468874B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14382209 2014-06-02
EP14382209.6 2014-06-02
PCT/EP2015/001115 WO2015185209A1 (en) 2014-06-02 2015-06-02 Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain

Publications (2)

Publication Number Publication Date
KR20170012444A KR20170012444A (ko) 2017-02-02
KR102468874B1 true KR102468874B1 (ko) 2022-11-17

Family

ID=50972618

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167036612A Active KR102468874B1 (ko) 2014-06-02 2015-06-02 통증에 대하여 다중모드 활성을 갖는 １-옥사-４,９-디아자스피로 운데칸 화합물의 알킬 유도체

Country Status (21)

Country Link
US (2) US10246465B2 (cg-RX-API-DMAC7.html)
EP (1) EP3149006B1 (cg-RX-API-DMAC7.html)
JP (1) JP6611736B2 (cg-RX-API-DMAC7.html)
KR (1) KR102468874B1 (cg-RX-API-DMAC7.html)
CN (1) CN106414457B (cg-RX-API-DMAC7.html)
AR (1) AR100715A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015271248B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016027825B1 (cg-RX-API-DMAC7.html)
CA (1) CA2949573C (cg-RX-API-DMAC7.html)
IL (1) IL249016B (cg-RX-API-DMAC7.html)
MX (1) MX2016015760A (cg-RX-API-DMAC7.html)
MY (1) MY177365A (cg-RX-API-DMAC7.html)
NZ (1) NZ726476A (cg-RX-API-DMAC7.html)
PH (1) PH12016502307B1 (cg-RX-API-DMAC7.html)
RU (1) RU2720406C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201810660QA (cg-RX-API-DMAC7.html)
TN (1) TN2016000509A1 (cg-RX-API-DMAC7.html)
TW (1) TWI685497B (cg-RX-API-DMAC7.html)
UA (1) UA124049C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015185209A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201608079B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201615643A (zh) 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性之１－氧雜－４，９－二氮雜螺十一烷化合物之烷基與芳基衍生物
AR106444A1 (es) * 2015-10-23 2018-01-17 Esteve Labor Dr Compuestos oxaazaespíricos con actividad contra el dolor
RS59956B1 (sr) 2015-10-23 2020-03-31 Esteve Pharmaceuticals Sa Oksa-diazaspiro jedinjenja koja imaju aktivnost protiv bola
TN2018000122A1 (en) * 2015-11-16 2019-10-04 Esteve Labor Dr Oxadiazaspiro compounds for the treatment of drug abuse and addiction
US10807970B2 (en) * 2016-05-20 2020-10-20 Esteve Pharmaceuticals, S.A. Tetrahydropyran and thiopyran derivatives having multimodal activity against pain
FI3697795T3 (fi) * 2017-10-17 2024-02-23 Acondicionamiento Tarrasense (R)-9-(2,5-difluorifenetyyli)-4-etyyli-2-metyyli-1-oksa-4,9-diatsaspiro[5.5]undekan-3-onin suoloja
WO2019158634A1 (en) 2018-02-16 2019-08-22 Esteve Pharmaceuticals, S.A. Deuterated derivatives of 9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
WO2019180188A1 (en) * 2018-03-23 2019-09-26 Esteve Pharmaceuticals, S.A. Aminopropoxyphenyl and benzyl 1-oxa-4,9-diazaspiroundecane derivatives having multimodal activity against pain
WO2020157026A1 (en) * 2019-01-28 2020-08-06 Esteve Pharmaceuticals, S.A. Hydroxylated derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
WO2021018824A1 (en) 2019-07-31 2021-02-04 Esteve Pharmaceuticals, S.A. Use of (r)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one for the treatment of nociceptive pain, neuropathic pain, osteoarthritis pain and cancer pain, while having reduced side effects compared to opioids
WO2024105225A1 (en) 2022-11-18 2024-05-23 Universitat De Barcelona Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120264749A1 (en) 2011-03-14 2012-10-18 Sara Sabina Hadida-Ruah Morpholine-spirocyclic piperidine amides as modulators of ion channels

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2133610B1 (cg-RX-API-DMAC7.html) * 1971-04-15 1975-10-31 Sumitomo Chemical Co
US4332804A (en) * 1981-03-23 1982-06-01 Syntex (U.S.A.) Inc. 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones
US4353900A (en) * 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones
US6114541A (en) 1997-03-10 2000-09-05 Hoffmann-La Roche Inc. Method for the preparation of α-Bromo-Lactam derivatives
RU2477136C2 (ru) * 2004-03-03 2013-03-10 Вайтал Хэлф Сайнсис Пти Лтд Алкалоидные составы
DE102005030051A1 (de) 2005-06-27 2006-12-28 Grünenthal GmbH Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102005030061A1 (de) 2005-06-27 2006-12-28 Behr Gmbh & Co. Kg Klimagerät
PT1961744E (pt) 2005-11-18 2013-05-15 Ono Pharmaceutical Co Composto que contém um grupo básico e sua utilização
CN101622241B (zh) 2007-03-01 2013-05-22 田边三菱制药株式会社 苯并咪唑化合物及其医药用途
EP1982714A1 (en) 2007-04-16 2008-10-22 Laboratorios del Dr. Esteve S.A. Pyrano-pyrazole-amines
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
EP2197876A1 (en) 2007-08-29 2010-06-23 Glaxosmithkline LLC Thiazole and oxazole kinase inhibitors
CN102083839B (zh) 2008-02-06 2014-03-26 阿斯利康(瑞典)有限公司 化合物
GB201107985D0 (en) 2011-05-13 2011-06-29 Astrazeneca Ab Process
US9751881B2 (en) 2013-07-31 2017-09-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
TW201615643A (zh) 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性之１－氧雜－４，９－二氮雜螺十一烷化合物之烷基與芳基衍生物
TW201615642A (zh) 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性的１－氧雜－４，９－二氮雜螺十一烷化合物之醯胺衍生物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120264749A1 (en) 2011-03-14 2012-10-18 Sara Sabina Hadida-Ruah Morpholine-spirocyclic piperidine amides as modulators of ion channels

Also Published As

Publication number Publication date
MX2016015760A (es) 2017-04-10
CN106414457A (zh) 2017-02-15
PH12016502307B1 (en) 2020-02-28
BR112016027825A2 (cg-RX-API-DMAC7.html) 2017-08-22
RU2016150518A3 (cg-RX-API-DMAC7.html) 2019-01-21
IL249016A0 (en) 2017-01-31
WO2015185209A1 (en) 2015-12-10
EP3149006B1 (en) 2020-09-09
UA124049C2 (uk) 2021-07-14
US10246465B2 (en) 2019-04-02
CA2949573C (en) 2023-07-18
AR100715A1 (es) 2016-10-26
KR20170012444A (ko) 2017-02-02
JP2017516818A (ja) 2017-06-22
SG10201810660QA (en) 2018-12-28
RU2720406C2 (ru) 2020-04-29
US20170313723A1 (en) 2017-11-02
TN2016000509A1 (en) 2018-04-04
ZA201608079B (en) 2017-09-27
AU2015271248A1 (en) 2016-12-15
TWI685497B (zh) 2020-02-21
IL249016B (en) 2020-05-31
NZ726476A (en) 2023-07-28
JP6611736B2 (ja) 2019-11-27
MY177365A (en) 2020-09-14
EP3149006A1 (en) 2017-04-05
CN106414457B (zh) 2020-04-17
AU2015271248B2 (en) 2019-10-31
RU2016150518A (ru) 2018-07-16
US20190177337A1 (en) 2019-06-13
PH12016502307A1 (en) 2017-02-13
SG11201609632UA (en) 2016-12-29
BR112016027825B1 (pt) 2023-03-28
CA2949573A1 (en) 2015-12-10
TW201617352A (zh) 2016-05-16

Similar Documents

Publication Publication Date Title
JP6611736B2 (ja) 疼痛に対する多様な活性を有する１−オキサ−４，９−ジアザスピロウンデカン化合物のアルキル誘導体
EP3442959A1 (en) Piperidinylalkylamide derivatives having multimodal activity against pain
JP2017516819A (ja) 疼痛に対する多様な活性を有する１−オキサ−４，９−ジアザスピロウンデカン化合物のアルキルおよびアリール誘導体
JP2017516817A (ja) 疼痛に対する多様な活性を有する１−オキサ−４，９−ジアザスピロウンデカン化合物のアミド誘導体
JP2017535545A (ja) 疼痛に対する多様な活性を有するスピロ−イソキノリン−１，４’−ピペリジン化合物
US10022359B2 (en) 1,9-diazaspiro undecane compounds having multimodal activity against pain
US20190031615A1 (en) 3-ethyl-3-phenylazepane derivatives having multimodal activity against pain
US10189828B2 (en) 1-methylpyrazole-piperazine compounds having multimodal activity against pain
US10071968B2 (en) Methyl-1H-pyrazole alkylamine compounds having multimodal activity against pain
EP3548490A1 (en) 2-phenyl-2h-pyrazolo[3,4-d]pyridazine derivatives having activity against pain
US10508114B2 (en) Spiro-isoquinoline-4,4′-piperidine compounds having multimodal activity against pain
WO2020157026A1 (en) Hydroxylated derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
US10351549B2 (en) Amide derivatives having multimodal activity against pain
US20200010457A1 (en) Tetrahydropyran and tetrahydrothiopyran amide derivatives having multimodal activity against pain
WO2018153545A1 (en) Piperidine methanone derivatives having multimodal activity against pain
WO2018153546A1 (en) Tetrahydropyran and tetrahydrothiopyran methanone derivatives having multimodal activity against pain
HK1235773A1 (en) Amide derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
HK1235773B (en) Amide derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20161227

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200515

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220104

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220613

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220104

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220613

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20220504

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20220817

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20220802

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20220613

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20220504

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20221115

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20221115

End annual number: 3

Start annual number: 1

PG1601 Publication of registration